Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.58 |
| ▸ | MAPT | P10636 | 4/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.58 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | ESR1 | P03372 | 2/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | RECQL | P46063 | 1/20 | 0.49 |
| ▸ | ELANE | P08246 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | BCL9 | O00512 | 1/20 | 0.42 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL383482 | 0.93 | KMT2A (0.57) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL28340805 | 0.83 | KMT2A (0.66) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL23843934 | 0.83 | KMT2A (0.60) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL28370277 | 0.81 | KMT2A (0.58) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL5711151 | 0.81 | ALDH1A1 (0.57) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL17449174 | 0.79 | KMT2A (0.55) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL7928066 | 0.78 | KMT2A (0.53) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL3681681 | 0.77 | KMT2A (0.53) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL27557226 | 0.76 | BCL9 (0.74) | KMT2AMAPTALDH1A1HTTHSD17B10 | |
| SCHEMBL17138135 | 0.76 | LMNA (0.52) | KMT2AMAPTALDH1A1HTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576119-B2 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2009-08-18 | — | — | US | claimed |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ISIS PHARMACEUTICALS, INC. (US) | 2008-01-24 | — | — | US | claimed |
| US-7202264-B2 | Supports such as glass and styrene polymers functionalized with tricyclic hetercyclic anhydrides and imides, used in the preparation of oligonucleotides | ISIS PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | claimed |
| EP-1670810-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLI CSUGAR MOIETIES AT THE TERMINI | Isis Pharmaceuticals, Inc. (US) | 2006-06-21 | — | — | EP | claimed |
| US-20050208588-A1 | Supports for oligomer synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2005-09-22 | — | — | US | claimed |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | IONIS PHARMACEUTICALS, INC. | 2005-03-17 | — | — | US | claimed |
| WO-2005023825-A2 | GAPPED OLIGOMERIC COMPOUNDS HAVING LINKED BICYCLIC SUGAR MOIETIES AT THE TERMINI | ISIS PHARMACEUTICALS, INC. (US) | 2005-03-17 | — | — | WO | claimed |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | ISIS PHARMACEUTICALS, INC. | 2005-03-10 | — | — | US | claimed |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | ISIS PHARMACEUTICALS, INC. | 2004-12-02 | — | — | US | claimed |
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | CHATTOPADHYAYA JYOTI (SE) | 2004-07-22 | — | — | US | claimed |
| US-6124484-A | Recovery of triarylmethyl halide protecting groups cleaved during oligonucleotide synthesis | ISIS PHARMACEUTICALS, INC. (US) | 2000-09-26 | — | — | US | claimed |
| US-5721350-A | Deuterated nucleosides | CHATTOPADHYAYA JYOTI (SE) | 1998-02-24 | — | — | US | claimed |
| JP-H09510206-A | — | — | 1997-10-14 | — | — | JP | claimed |
| US-5623068-A | Synthesis of DNA using substituted phenylacetyl-protected nucleotides | BECKMAN INSTRUMENTS, INC. (US) | 1997-04-22 | — | — | US | claimed |
| EP-0749436-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1996-12-27 | — | — | EP | claimed |
| US-5574146-A | Oligonucleotide synthesis with substituted aryl carboxylic acids as activators | BECKMAN INSTRUMENTS, INC. (US) | 1996-11-12 | — | — | US | claimed |
| EP-0725787-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006853-A1 | ACTIVATED NUCLEOSIDE PHOSPHORAMIDITES AND METHODS FOR THE PREPARATION AND USE THEREOF | BECKMAN INSTRUMENTS, INC. (US) | 1996-03-07 | — | — | WO | claimed |
| WO-1995024413-A1 | COMPOSITIONS AND METHODS FOR USE IN THE SYNTHESIS OF OLIGONUCLEOTIDES | BECKMAN INSTRUMENTS, INC. (US) | 1995-09-14 | — | — | WO | claimed |
| WO-1993025566-A1 | DEUTERATED NUCLEOSIDES | CHATTOPADHYAYA JYOTI (SE) | 1993-12-23 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040142946-A1 | Modified nucleosides and nucleotides and use thereof | RNASEH1, RNASEL, NSUN2 | KMT2A 1336/4885MAPT 4857/4885ALDH1A1 4684/4885 |
| US-20080021224-A1 | SUPPORTS FOR OLIGOMER SYNTHESIS | ILK, NOP2, PFAS | KMT2A 2924/4885MAPT 301/4885ALDH1A1 4121/4885 |
| US-20050059066-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | KMT2A 2982/4885MAPT 2702/4885ALDH1A1 4296/4885 |
| US-20050053981-A1 | Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini | OGG1, UNG, PCNA | KMT2A 2982/4885MAPT 2702/4885ALDH1A1 4296/4885 |
| US-20050208588-A1 | Supports for oligomer synthesis | ILK, NOP2, PFAS | KMT2A 2924/4885MAPT 301/4885ALDH1A1 4121/4885 |
| US-20040242897-A1 | Universal support media for synthesis of oligomeric compounds | NEFM, POLRMT, POLM | KMT2A 3200/4885MAPT 1344/4885ALDH1A1 4790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.